NISA INVESTMENT ADVISORS, LLC - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.

Quarter-by-quarter ownership
NISA INVESTMENT ADVISORS, LLC ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$23,805
-30.0%
1,870
-0.6%
0.00%
Q2 2023$34,008
+161842.9%
1,882
+56.8%
0.00%
Q1 2023$21
-22.2%
1,200
-1.7%
0.00%
Q4 2022$27
-99.7%
1,221
+1.8%
0.00%
Q3 2022$10,000
-95.9%
1,200
-92.5%
0.00%
-100.0%
Q1 2022$243,00016,1000.00%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Octagon Capital Advisors LP 831,267$22,419,0005.52%
Aquilo Capital Management, LLC 1,099,944$29,665,0005.39%
BVF INC/IL 2,005,862$54,098,0002.11%
Casdin Capital, LLC 1,115,455$30,084,0000.75%
Soleus Capital Management, L.P. 120,900$3,261,0000.51%
Eagle Health Investments LP 57,090$1,540,0000.49%
Centiva Capital, LP 358,863$7,220,0000.45%
VIKING GLOBAL INVESTORS LP 3,937,914$106,206,0000.29%
ArrowMark Colorado Holdings LLC 1,003,447$27,063,0000.21%
Perceptive Advisors 375,256$10,121,0000.15%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders